ReviewFrontiers in cellular and infection microbiology2020
Dysfunctional Innate Immune Responses and Severe Dengue.
Review in Frontiers in cellular and infection microbiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 70 citations in OpenAlex.
- Efficacy of rupatadine in reducing the incidence of dengue haemorrhagic fever in patients with acute dengue: A randomised, double blind, placebo-controlled trial.PLoS neglected tropical diseases · 2022Trial
- Bulk transcriptomics of peripheral blood mononuclear cells delineates systems-level immune dysregulation in pediatric dengue infection.NPJ systems biology and applications · 2026Article
- Progression of dengue during an outbreak (2024) in Dhaka, Bangladesh: a hospital based longitudinal study.The Lancet regional health. Southeast Asia · 2026Article
- Efficacy of Probiotics and Postbiotics in Treating Dengue Fever - A Potential Strategy to Reduce Antibody-dependent Enhancement.Probiotics and antimicrobial proteins · 2026Review
- Metabolic and cardiovascular comorbidities as predictors of severe dengue in Vietnamese adults: a retrospective study, 2022-2024.Osong public health and research perspectives · 2026Article
- Innate Immune and Inflammatory Responses to Dengue Virus Infection.Current topics in microbiology and immunology · 2026Review
- Dengue Fever and Its Burden in Burkina Faso: An Overview.Reviews in medical virology · 2026Review
- Dengue and severe dengue.Clinical microbiology reviews · 2025Review
- Mimicry in the Bite: Shared Sequences BetweenProteomes · 2025Article
- Genetic ancestry shapes dengue virus infection in human skin explants.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Pathogenesis and clinical management of arboviral diseases.World journal of virology · 2025Review
- Identification of HLA ligands in dengue patients by multiplex PCR-SSP method.Molecular biology reports · 2025Article
- Vitamin D enhances antiviral responses in dengue virus-infected macrophages by modulating early-response gene expression.PloS one · 2025Article
- Prognostic prediction of dengue hemorrhagic fever in pediatric patients with suspected dengue infection: A multi-site study.PloS one · 2025Article
- Clinical features and laboratory indicators of dengue infection in China: a retrospective study of adult patients in a hospital of traditional Chinese medicine.Frontiers in medicine · 2025Article
- Dysregulated immune cell responses in severe dengue pathogenesis.Frontiers in immunology · 2025Review
- Vitamin D Deficiency is Associated With Dengue Severity in Pediatric Cases, Eastern India.Journal of tropical medicine · 2025Article
- Significance of diagnostic and therapeutic potential of serum endothelial and inflammatory biomarkers in defining disease severity of dengue infected patients.Medical microbiology and immunology · 2024Article
- A Scoping Review of Arthropod-Borne Flavivirus Infections in Solid Organ Transplant Recipients.Transplant infectious disease : an official journal of the Transplantation Society · 2024Article
- Are viral loads in the febrile phase a predictive factor of dengue disease severity?BMC infectious diseases · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
Abstract
Although infection with the dengue virus (DENV) causes severe dengue, it causes a mild self-limiting illness in the majority of individuals. There is emerging evidence that an aberrant immune response in the initial stages of infection lead to severe disease. Many inflammatory cytokines, chemokines, and lipid mediators are significantly higher in patients with severe dengue compared to those who develop mild infection, during febrile phase of illness. Monocytes, mast cells, and many other cells of the immune system, when infected with the DENV, especially in the presence of poorly neutralizing antibodies, leads to production of pro-inflammatory cytokines and inhibition of interferon signaling pathways. In addition, production of immunosuppressive cytokines such as IL-10 further leads to inhibition of cellular antiviral responses. This dysregulated and aberrant immune response leads to reduced clearance of the virus, and severe dengue by inducing a vascular leak and excessive inflammation due to high levels of inflammatory cytokines. Individuals with comorbid illnesses could be prone to more severe dengue due to low grade endotoxemia, gut microbial dysbiosis and an altered phenotype of innate immune cells. The immunosuppressive and inflammatory lipid mediators and altered phenotype of monocytes are likely to further act on T cells and B cells leading to an impaired adaptive immune response to the virus. Therefore, in order to identify therapeutic targets for treatment of dengue, it would be important to further characterize these mechanisms in order for early intervention. In this review, we discuss the differences in the innate immune responses in those who progress to develop severe dengue, compared to those with milder disease in order to understand the mechanisms that lead to severe dengue.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.